News

The project will help the company keep pace with a growing demand for the development and use of biologics, which currently represents nearly 50% of its overall pipeline.

As part of the deal, Yabao will receive exclusive rights to discover, develop and commercialise new products in China, Taiwan and Hong Kong, while MRC Technology will retain

In the coming months, the European Commission (EC) is expected to make a final decision on granting marketing authorization for Cerdelga in the European Union (EU). In August,

Victoza (liraglutide) is a once-daily human the human glucagon-like peptide-1 (GLP-1) analogue with an amino acid sequence 97% similar to endogenous human GLP-1. It works by stimulating the

The EMA committee’s positive opinion is based on pivotal data from the replicate Phase III INPULSIS trials which included about 1,066 patients from 24 countries. Results from these

Dr. Reddy’s ANDA is approved by the United States Food & Drug Administration (USFDA). The Allegra-D 12 Hour brand has U.S. sales of approximately $49.8 million for the

As part of the acquisition agreement, Apellis obtained the necessary intellectual property rights to develop its complement inhibitor drug compound (APL-2) in ophthalmology and plans its first clinical

The Notice of Allowance is for U.S. Patent Application No. 14/230,053, "Compositions for Treatment of Attention Deficit Hyperactivity Disorder" owned by Highland’s wholly owned subsidiary, Ironshore Pharmaceuticals &

The grant, with additional funding from Heptares, will support a three-year research project aimed at developing first-in-class, selective and orally available small molecule GLP-1 receptor antagonists for the